Key Takeaway
Compare semaglutide weight loss results at every dose level from 0.25 mg to 2.4 mg. Learn how dose affects your outcomes and what to expect at each titration step.
Semaglutide weight loss is strongly dose-dependent, with clinical data showing that patients on 2.4 mg lose roughly three times more weight than those on 0.5 mg. Understanding the relationship between dose and results helps you set appropriate expectations at each stage of treatment and have informed conversations with your provider about dose improvement.
Semaglutide is available at multiple dose levels across its branded formulations (Ozempic: 0.25 mg to 2.0 mg. Wegovy: 0.25 mg to 2.4 mg). Each dose produces a different level of weight loss, and the data from multiple clinical trials gives us a clear picture of what to expect at each level. semaglutide overview
Weight Loss Data by Dose Level
thorough Dose-Response Table
| Dose (Weekly) | Primary Data Source | Avg Weight Loss (%) | Avg Pounds Lost (from ~230 lb baseline) | % Achieving 10%+ Loss |
|---|---|---|---|---|
| 0.25 mg | Titration phase only | 1% to 2% | 2 to 5 lbs | N/A (titration) |
| 0.5 mg | SUSTAIN trials | 3% to 5% | 7 to 12 lbs | ~15% to 20% |
| 1.0 mg | SUSTAIN/STEP 8[1] | 5% to 7% | 12 to 16 lbs | ~25% to 35% |
| 1.7 mg | Wegovy titration data | 8% to 11% | 18 to 25 lbs | ~45% to 55% |
| 2.0 mg | SUSTAIN FORTE | 6% to 9% | 14 to 21 lbs | ~30% to 40% |
| 2.4 mg | STEP 1[2], 3, 5 | 14% to 16% | 32 to 37 lbs | ~69% |
What Each Dose Level Does
0.25 mg: The Starting Dose
This dose is purely for acclimatization. It isn't intended to produce significant weight loss. Your body uses this period to adjust to semaglutide's effects on gastric emptying and appetite signaling. Most patients lose 1% to 2% of body weight (2 to 5 pounds) during their 4 weeks at this dose. For a complete cost breakdown, see our compare GLP-1 providers.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Even at this low dose, you'll likely notice some appetite reduction. Meals may feel more filling, and between-meal hunger may decrease slightly. Nausea is most common during this introductory phase and usually improves as your body adapts. semaglutide starting dose guide
0.5 mg: First Therapeutic Dose
At 0.5 mg, semaglutide begins producing meaningful appetite suppression and blood sugar improvements. This is the first dose at which weight loss accelerates beyond what you would typically see with diet changes alone. The SUSTAIN trials showed average weight loss of 3% to 5% at this dose in patients with type 2 diabetes over 30 to 56 weeks.
For patients without diabetes using this dose primarily for weight management, results are often somewhat higher. But 0.5 mg is generally considered below the optimal dose for weight loss, and most patients benefit from titrating higher.
1.0 mg: Standard Ozempic Dose
The 1.0 mg dose is the standard maintenance dose for Ozempic (diabetes indication). At this level, appetite suppression is well-established and most patients experience consistent weekly weight loss. Clinical data shows 5% to 7% average body weight loss at this dose over extended treatment periods.
For many patients, 1.0 mg provides a good balance of weight loss efficacy and tolerability. Some patients remain at this dose long-term, particularly those using Ozempic for diabetes management where the primary goal is glycemic control with weight loss as a secondary benefit. Ozempic dosing for weight loss
1.7 mg: Wegovy Transition Dose
The 1.7 mg dose is part of Wegovy's titration schedule. While patients spend only 4 weeks at this dose before moving to 2.4 mg, the weight loss at 1.7 mg is notably higher than at 1.0 mg. This dose bridges the gap between the diabetes-focused doses and the full weight management dose.
Many patients report that the jump from 1.0 mg to 1.7 mg produces a noticeable increase in appetite suppression. Nausea may temporarily return or intensify with this dose increase, though it typically resolves within 1 to 2 weeks.
2.0 mg: Maximum Ozempic Dose
The 2.0 mg dose was introduced as a higher option for Ozempic to provide additional glycemic and weight loss benefits. The SUSTAIN FORTE trial showed that 2.0 mg produced more weight loss than 1.0 mg, with an average of 13.4 pounds over 40 weeks compared to 10.1 pounds.
For patients who are taking Ozempic and want more weight loss than 1.0 mg provides, stepping up to 2.0 mg is a viable option. But the weight loss at 2.0 mg still falls short of what the 2.4 mg Wegovy dose produces, due to both the lower dose and the different patient populations studied.
2.4 mg: Full Weight Management Dose
The 2.4 mg dose, available through Wegovy and some compounded formulations, is the dose that produced the headline results from the STEP trial program. At this level, semaglutide delivers its maximum appetite-suppressing and metabolic effects.
The STEP 1 trial showed 14.9% average weight loss at 2.4 mg over 68 weeks. The STEP 3 trial[3], which combined 2.4 mg with intensive behavioral therapy, achieved 16%. About one-third of patients on this dose lost 20% or more of their body weight. semaglutide before and after at 2.4 mg
The Dose-Response Curve Explained
Semaglutide's dose-response relationship isn't perfectly linear. The weight loss increase from 0.25 mg to 1.0 mg is proportionally smaller than the increase from 1.0 mg to 2.4 mg. This suggests that the appetite and metabolic effects of semaglutide become disproportionately stronger at higher doses.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →This has important clinical implications. A patient losing 5% of body weight at 1.0 mg shouldn't assume they will lose 12% at 2.0 mg (a simple doubling). The actual increase is typically greater than dose-proportional, meaning the 2.4 mg dose may produce results 2 to 3 times greater than the 1.0 mg dose in the same patient.
Factors That Modify Dose-Dependent Results
Diabetes Status
At every dose level, patients with type 2 diabetes lose less weight than patients without diabetes. This is consistent across all semaglutide trials. The difference is thought to relate to insulin resistance, concurrent diabetes medications (some of which promote weight gain), and differences in metabolic flexibility. semaglutide weight loss with diabetes
Tolerability
Not every patient can tolerate the highest dose. Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) increase with dose. About 5% to 7% of patients in the STEP trials discontinued treatment due to adverse events. Finding the highest dose you can comfortably tolerate over the long term is more important than forcing yourself to the maximum.
Individual Variation
Some patients achieve excellent results at lower doses, while others need the full 2.4 mg to see meaningful weight loss. Genetic differences in GLP-1 receptor sensitivity, gut hormone production, and metabolic rate all contribute to this variation. Your response at any given dose is somewhat unpredictable until you try it.
How Providers Determine Your Optimal Dose
At FormBlends, our providers use several criteria to determine the right semaglutide dose for each patient.
- Response to current dose: If you're losing weight steadily at a lower dose with good tolerability, there may be no need to increase
- Tolerability: If a dose increase causes persistent nausea or vomiting, stepping back to the previous dose may be appropriate
- Weight loss goals: Patients with more weight to lose may benefit from reaching the highest tolerable dose
- Health markers: If blood sugar, blood pressure, or other metabolic markers are responding well at a lower dose, the overall benefit may already be significant
- Side effect profile: Some patients experience side effects that limit dose escalation, and the risk-benefit calculation must be individualized
Frequently Asked Questions
Can I stay on a lower dose of semaglutide if it's working for me?
Absolutely. If you're achieving satisfactory weight loss at 1.0 mg or 1.7 mg with good tolerability, there's no requirement to increase to 2.4 mg. The best dose is the one that provides meaningful results with acceptable side effects. Your provider can help you weigh the potential benefits of a dose increase against the risks.
Will I lose weight faster if I skip to a higher dose?
Skipping dose levels isn't recommended. The titration schedule reduces the risk of severe gastrointestinal side effects, which can lead to dehydration, malnutrition, and treatment discontinuation. Patients who follow the gradual titration schedule are more likely to stay on treatment long enough to achieve their full weight loss potential.
Is the 2.4 mg dose always better than 1.0 mg?
"Better" depends on your individual situation. On average, 2.4 mg produces significantly more weight loss. But if 1.0 mg is producing meaningful results with minimal side effects, and 2.4 mg causes intolerable nausea, then 1.0 mg may be the better choice for you. The goal is sustained treatment with consistent progress.
What if I can't tolerate the higher doses?
If you experience persistent side effects at a higher dose, your provider may recommend returning to the previous well-tolerated dose. In some cases, dietary adjustments (eating smaller meals, avoiding high-fat foods) can improve tolerability and allow you to retry the higher dose after a few weeks. managing semaglutide side effects by dose
Does compounded semaglutide work the same way at each dose?
Compounded semaglutide contains the same active molecule and should produce similar dose-dependent effects. But the quality and consistency of compounded medications depend on the compounding pharmacy. At FormBlends, we work exclusively with licensed, regulated compounding pharmacies to ensure medication quality. compounded semaglutide results
Medical References
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2023;327(2):138-150. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
Find Your Optimal Dose with FormBlends
FormBlends providers specialize in finding the right semaglutide dose for each patient. Through our physician-supervised telehealth platform, we guide your dose titration, monitor your response at each level, and help you reach the dose that delivers the best balance of weight loss and tolerability. get started with FormBlends
Start your consultation today and work with our clinical team to improve your semaglutide treatment.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →